Every 10-Q that RxSight, Inc. (RXST) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RXST and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RXST filings page.
RxSight, Inc. reported Q2 2026 revenue of $33,741 (amounts in thousands of dollars), compared with $33,637 a year earlier. Product sales declined to $27,241, while license and collaboration revenue of $6,500 from a new Alcon agreement offset much of that change. Q2 net loss was $12,097, or $0.29 per share.
For the first six months of 2026, revenue was $64,634 and net loss $27,981, with operating cash outflows of $20,429 (all in thousands). Liquidity remained strong with $208.8 million in cash, cash equivalents and short‑term investments. RxSight ended June with 1,166 installed Light Delivery Devices and approximately 357,000 cumulative Light Adjustable Lens implants.
The Alcon collaboration includes a $60 million upfront payment, of which $10.0 million is the initial transaction price, with $6.5 million recognized as license revenue and $3.5 million deferred. The remaining $50.0 million is refundable within 120 days. Alcon may also owe $70 million, $30 million and $40 million milestones plus 30% royalties on Collaboration Product net sales.
RxSight, Inc. reported lower quarterly sales and a wider loss as growth in its premium cataract lens business slowed. For the three months ended March 31, 2026, sales were $30.9 million, down 18.5% from the prior year, mainly from fewer Light Delivery Device (LDD) sales, while Light Adjustable Lens (LAL) revenue was roughly flat.
Gross profit was $23.5 million with a gross margin of 76.1%, helped by a higher mix of LAL sales. Operating expenses rose to $41.3 million, driven by higher selling, general and administrative spending, and the net loss nearly doubled to $15.9 million. RxSight ended the quarter with $217.9 million in cash, cash equivalents and short-term investments and expects to continue operating losses while investing in commercial expansion and R&D.
RxSight, Inc. reported lower quarterly sales and a wider loss while maintaining a strong cash position as it scales its light-adjustable intraocular lens business. For the three months ended September 30, 2025, sales were $30,340 (in thousands), down from $35,314 (in thousands) a year earlier, with gross profit of $24,227 (in thousands) and an operating loss of $12,178 (in thousands). Net loss was $9,816 (in thousands), or $0.24 per share, compared with a net loss of $6,338 (in thousands), or $0.16 per share.
For the first nine months of 2025, sales were $101,871 (in thousands) versus $99,713 (in thousands) in 2024, and net loss increased to $29,792 (in thousands) from $21,517 (in thousands). Cash, cash equivalents and short-term investments totaled $227,500 (in thousands) as of September 30, 2025, and management believes this will fund operations for at least 12 months, though it still expects ongoing operating losses.
RxSight had 1,109 Light Delivery Devices installed and approximately 276,000 Light Adjustable Lenses implanted since inception, reflecting continued commercial adoption. The company also disclosed consolidated securities class actions and shareholder derivative suits seeking unspecified damages related to its disclosures, which it contests and intends to defend vigorously.